AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06288464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Fibre
Description: Patients will be assigned to stoma feeding by the Colorectal Surgeon, which will be managed by the stoma nurses for the duration, approximately 4 weeks, of feeding. For the final 7-14 days (minimum 7 days) of feeding, 10g of soluble fibre will be added to 100ml of Ensure™ (or equivalent liquid nutrient feed) before instillation into the stoma on a daily basis. The soluble fibre will be provided in 10g portions and should be added to the newly-opened bottle of ensure and shaken to mix well.
Study NCT06153680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14.
Study NCT05879094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morton extension
Description: A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
Study NCT05901389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
Study NCT05901389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
Study NCT06509191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study NCT05935761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
Study NCT05935761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
Study NCT05935761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator arms, except placebo dispensed
Study NCT05840263 — intervention group
Intervention type: BEHAVIORAL
Intervention: Qualitative interview
Description: Qualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
Study NCT05840263 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Interviews
Description: The objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
Study NCT06576921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Combined With Chemotherapy
Description: Serplulimab (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
Study NCT06576921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo combined with Chemotherapy
Description: Placebo (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
Study NCT05775965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Description: Rivaroxaban 10mg daily for 35 days post hip fracture surgery
Study NCT05775965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA) 81mg Oral Tablet
Description: acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
Study NCT06469944 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion.
Study NCT06469944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion.
Study NCT06469944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Tirumotecan (sac-TMT)
Description: Administered via IV infusion.
Study NCT06469944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered via oral tablet.
Study NCT06469944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered via oral tablet.
Study NCT06469944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Administered via IV infusion.
Study NCT06469944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin
Description: Administered via IV infusion.
Study NCT06469944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Administered via IV infusion
Study NCT06469944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered via IV infusion
Study NCT06399653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical transcutaneous vagus nerve stimulation (active comparator)
Description: Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
Study NCT06399653 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical transcutaneous vagus nerve stimulation (sham comparator)
Description: Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
Study NCT04985487 — intervention group
Intervention type: OTHER
Intervention: brolucizumab
Description: Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
Study NCT05723809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussive Therapy Device
Description: Same as group description
Study NCT05723809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Same as group description
Study NCT05723809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Same as group description
Study NCT05926479 — intervention group
Intervention type: OTHER
Intervention: Translating the Questionnaire into Turkish and Related Processes
Description: The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
Study NCT05926479 — intervention group
Intervention type: OTHER
Intervention: Validity
Description: The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
Study NCT05926479 — intervention group
Intervention type: OTHER
Intervention: Reliability
Description: The reliability of the materials will be tested with Cronbach alpha.
Study NCT05594472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozonated olive oil
Description: Topical treatment will be applied for 5 consecutive days on the erosions.
Study NCT05594472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical garamycin cream
Description: Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
Study NCT06218680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
Study NCT06218680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
Study NCT00995059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation
Study NCT00995059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo transplantation
Study NCT00995059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00995059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00995059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT00995059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given orally
Study NCT04271332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: Arbaclofen tablet
Study NCT04271332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Manufactured to match Arbaclofen in size, shape, color and taste
Study NCT06465511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive clinic
Description: During the visit, each patient will receive a personalized feedback summary, including an assessment and recommendation on managing physical and psychological symptoms, an evaluation and recommendation on dietary advice, an assessment and recommendation on physical activity, and advice on managing potential psychosocial issues by the multidisciplinary team.
Study NCT06465511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: Self-management
Description: Each pamphlet given to the patients addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer progression) observed in Hong Kong patients with advanced or metastatic cancer, plus two on lifestyle recommendations (physical activity and eating well). All pamphlets are developed based on the self-management framework.
Study NCT05403827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-161
Description: K-161 Ophthalmic Solution
Study NCT05403827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Solution
Study NCT06413680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10597
Description: Administered as an intravenous (IV) infusion
Study NCT05726838 — intervention group
Intervention type: OTHER
Intervention: Inclisiran
Description: There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.
Study NCT06506721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double ballon device, Cook
Description: Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed.
Study NCT06506721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervix dilators, Dilapan-S
Description: A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed.
Study NCT05953480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Redasemtide
Description: Lyophilized white powder reconstituted in 0.9% saline for injection
Study NCT05953480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized white powder reconstituted in 0.9% saline for injection
Study NCT05639062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative-based card game
Description: This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
Study NCT06412549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health care practices and routines
Description: The scope of the project includes a diagnostic visit to participating hospitals, conducted by the coordinating center team, to understand existing protocols related to the management of invasive central nervous system devices (such as intracranial pressure monitoring catheters or external ventricular drains), as well as the physical infrastructure, human resources, and other precautions taken for the prevention and treatment of central nervous system infections. All recommendations in the intervention bundle for patient care will align with the guidelines of the National Health Surveillance Agency (ANVISA) and the best available scientific evidence for preventing infections associated with central nervous system devices.~* Provide the best care for patients with ICP and/or EVD, based on the best available evidence, with regard to the insertion and maintenance of catheters, as well as diagnosis and treatment in the presence of infection.~* Training of the multidisciplinary team.
Study NCT05353452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurology Based Collaborative Care
Description: Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
Study NCT05353452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC Neurological care
Description: Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
Study NCT00995059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given oral or IV
Study NCT04920877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infection Prevention
Description: Preventing central catheter-related bloodstream infections in intensive care units
Study NCT00995059 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation
Study NCT05625022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lianhua Qingke tablets
Description: Lianhua Qingke tablets: 4 tablets once, three times daily
Study NCT05510505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20 monoclonal antibody
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Study NCT05510505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Study NCT04999189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app forDiabetes (Tessera Multimedia, 2020)
Description: Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
Study NCT06036589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA and BAM8-22
Description: CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study NCT06036589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle and BAM8-22 application
Description: Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study NCT06036589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA
Description: CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm
Study NCT06036589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vehicle
Description: Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
Study NCT05316935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
Study NCT05316935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 2.5mg po qd and no more than 24 weeks